Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma
Author Information
Author(s): Athanasios Xanthopoulos, Torsten Bauer, Torsten Blum, Jens Kollmeier, Nicolas Schönfeld, Monika Serke
Primary Institution: HELIOS Klinikum Emil von Behring, Berlin, Germany
Hypothesis
The study aimed to investigate the efficacy and safety of oxaliplatin combined with gemcitabine in patients with malignant pleural mesothelioma pretreated with pemetrexed.
Conclusion
Patients with relapsed malignant pleural mesothelioma may benefit from treatment with oxaliplatin and gemcitabine without significant toxicity.
Supporting Evidence
- The median overall survival was 71.7 weeks.
- Partial response was observed in 6.9% of patients.
- The disease control rate was 44.8%.
Takeaway
This study looked at how well two cancer drugs work together for patients with a specific type of lung cancer that didn't respond to earlier treatment. It found that the combination can help some patients without causing serious side effects.
Methodology
The study enrolled consecutive patients with relapsed malignant pleural mesothelioma who were pretreated with a platin-pemetrexed-based chemotherapy and received oxaliplatin and gemcitabine in a structured regimen.
Limitations
The study's observational design and the heterogeneity of the patient population limit the generalizability of the results.
Participant Demographics
{"median_age":65,"gender_distribution":{"male":27,"female":2},"WHO_performance_status":{"0":5,"1":18,"2":3,"3":3},"asbestos_exposure":{"yes":17,"no":1,"not_defined":11}}
Statistical Information
Confidence Interval
{"overall_survival":"30.6–243.3 weeks","time_to_tumor_progression":"3.0–67.6 weeks"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website